Replies to post #79770 on Anavex Life Sciences Corp (AVXL)

[plexrec]

blu_1---could you expand on--explain--"My point is, don't expect improvement or stabilization of scores at 9 or 12 months at CTAD. That's now fair to 273. Be realistic and logical. Ignore the non scientists that don't take the aforementioned into account." don't get the point you are trying to make---good or bad for 2-73 ???TIA

[powerwalker]

blu, obviously, there is a lot we don't know that has occurred with the first extension, such as:

1) Did the dosage changed to the optimal amount after 26 weeks?

2) Why were term periods changed to 36/41 from 38/43 weeks and a 48/53 week term added?

3) Were any participants moved from combo- to mono-therapy (or visa versa though I don't know why)?

4) Why no release of the 9 month, i.e., the 36/41 weeks, data?

I sent questions on the last three to IR and have not received a reply, not surprisingly, as I did not expect one.

We have 5 more weeks before we learn what has occurred for those participants during the first extension period.

You are correct about speculating what the new data will reveal, but sometimes, it is exciting being Sherlock Holmes.